Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 369 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Polyzos, Stergios A  [Clear All Filters]
2018
Anastasilakis, A. D., Tournis S., Yavropoulou M. P., Polyzos S. A., & Makras P. (2018).  Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?. Calcif Tissue Int. 103(1), 107-108.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Makras P., Hawa G., Sonnleitner L., et al. (2018).  Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment.. Hormones (Athens). 17(4), 573-579.
Polyzos, S. A., Kountouras J., Anastasiadis S., Doulberis M., & Katsinelos P. (2018).  Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach?. Hepatology. 68(1), 389.
Polyzos, S. A., & Mantzoros C. S. (2018).  Outliers of bone metabolic diseases.. Metabolism. 80, 1-4.
Upadhyay, J., Polyzos S. A., Perakakis N., Thakkar B., Paschou S. A., Katsiki N., et al. (2018).  Pharmacotherapy of type 2 diabetes: An update.. Metabolism. 78, 13-42.
Kountouras, J., Doulberis M., Polyzos S. A., Papaefthymiou A., Kapetanakis N., Arapoglou S., et al. (2018).  Potential Impact of Active Helicobacter pylori Infection with or without Concomitant Metabolic Syndrome on Colorectal Cancer Invasion and Mortality.. Isr Med Assoc J. 20(11), 725-726.
Kountouras, J., Polyzos S. A., Katsinelos P., Anastasiadis S., Tzivras D., Doulberis M., et al. (2018).  Potential Impact of Helicobacter Pylori on Hepatic Encephalopathy Pathophysiology.. Dig Dis Sci. 63(4), 1087-1088.
Boziki, M., Polyzos S. A., Deretzi G., Kazakos E., Katsinelos P., Doulberis M., et al. (2018).  A potential impact of Helicobacter pylori-related galectin-3 in neurodegeneration.. Neurochem Int. 113, 137-151.
Kountouras, J., Polyzos S. A., Doulberis M., Zeglinas C., Artemaki F., Vardaka E., et al. (2018).  Potential impact of Helicobacter pylori-related metabolic syndrome on upper and lower gastrointestinal tract oncogenesis.. Metabolism. 87, 18-24.
Doulberis, M., Kotronis G., Thomann R., Polyzos S. A., Boziki M., Gialamprinou D., et al. (2018).  Review: Impact of Helicobacter pylori on Alzheimer's disease: What do we know so far?. Helicobacter. 23(1), 
Polyzos, S. A., & Margioris A. N. (2018).  Sarcopenic obesity.. Hormones (Athens). 17(3), 321-331.
Polyzos, S. A., & Mantzoros C. S. (2018).  Sixty-six years of Metabolism, Clinical and Experimental: The journey of a journal and opportunities and challenges looking ahead.. Metabolism. 78, A4-A9.
Anastasilakis, A. D., Polyzos S. A., & Makras P. (2018).  THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.. Eur J Endocrinol. 179(1), R31-R45.
Efstathiadou, Z. A., Kita M. D., & Polyzos S. A. (2018).  Thyroid dysfunction and non-alcoholic fatty liver disease.. Minerva Endocrinol. 43(3), 367-376.
2017
Kountouras, J., Kapetanakis N., Polyzos S. A., Katsinelos P., Gavalas E., Tzivras D., et al. (2017).  Active Infection Is a Risk Factor for Colorectal Mucosa: Early and Advanced Colonic Neoplasm Sequence.. Gut Liver. 11(5), 733-734.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2017).  Adipose tissue, obesity and non-alcoholic fatty liver disease.. Minerva Endocrinol. 42(2), 92-108.
Kountouras, J., Polyzos S. A., Katsinelos P., Zeglinas C., Artemaki F., Tzivras D., et al. (2017).  Cardio-cerebrovascular disease and Helicobacter pylori-related metabolic syndrome: We consider eradication therapy as a potential cardio-cerebrovascular prevention strategy.. Int J Cardiol. 229, 17-18.
Anastasilakis, A. D., Koulaxis D., Kefala N., Polyzos S. A., Upadhyay J., Pagkalidou E., et al. (2017).  Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD. Metabolism. 73, 1-8.
Anastasilakis, A. D., Polyzos S. A., Makras P., Aubry-Rozier B., Kaouri S., & Lamy O. (2017).  Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases.. J Bone Miner Res. 32(6), 1291-1296.
Kazakos, E. I., Dorrell N., Polyzos S. A., Deretzi G., & Kountouras J. (2017).  Comment on "Effect of biofilm formation by clinical isolates of Helicobacter pylori on the efflux-mediated resistance to commonly used antibiotics".. World J Gastroenterol. 23(33), 6194-6196.
Polyzos, S. A., Kountouras J., Mantzoros C. S., Polymerou V., & Katsinelos P. (2017).  Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial.. Diabetes Obes Metab. 19(12), 1805-1809.
Polyzos, S. A. (2017).  Endocrine and metabolic disorders interplaying with non-alcoholic fatty liver disease.. Minerva Endocrinol. 42(2), 89-91.
Kountouras, J., Polyzos S. A., Katsinelos P., Zeglinas C., Artemaki F., Tzivras D., et al. (2017).  Helicobacter pylori eradication to prevent cardio-cerebrovascular disease: Are current data useful for clinical practice?. Int J Cardiol. 233, 92.
Kountouras, J., Polyzos S. A., Katsinelos P., Tzivras D., Boziki M., Gavalas E., et al. (2017).  Helicobacter pylori on portal hypertension-related hepatic encephalopathy.. Immunopharmacol Immunotoxicol. 39(2), 105-106.
Kountouras, J., Polyzos S. A., Zeglinas C., & Katsinelos P. (2017).  Helicobacter pylori-related chronic hepatitis C infection and the risk for cardiovascular disease.. Liver Int. 37(7), 1082.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.